Akebia Therapeutics Stock Forecast NASDAQ:AKBA

Price Target and Analyst Ratings

Most Recent Rating

HC Wainwright is very positive about AKBA and gave it a "Buy" rating on March 15, 2021. The price target was changed from $9.00 to $6.00.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-03-15	Buy	Target Lowered by	HC Wainwright	$3.60	$9.00 → $6.00
2021-03-15	Overweight	Initiated by	Cantor Fitzgerald	$3.60	$8.00
2021-03-08	Overweight	Initiated by	Cantor Fitzgerald	$3.33	$8.00
2021-03-08	Buy	Target Lowered by	HC Wainwright	$3.33	$9.00 → $6.00
2021-01-29	Neutral - Underweight	Downgraded by	JPMorgan Chase & Co.	$3.24
2020-10-26	Buy	Target Lowered by	HC Wainwright	$2.84	$10.00 → $9.00
2020-09-04	Equal Weight	Target Lowered by	Morgan Stanley	$2.72	$12.00 → $3.00
2020-09-04	Buy	Target Lowered by	BTIG Research	$2.72	$26.00 → $6.00
2020-09-04	Buy	Target Lowered by	HC Wainwright	$2.72	$17.00 → $10.00
2020-09-04	Buy	Target Lowered by	Mizuho	$2.72	$17.00 → $6.00
2020-09-03	Overweight - Neutral	Downgraded by	JPMorgan Chase & Co.	$2.65
2020-08-11	Buy	Initiated by	Needham & Company LLC	$10.28	$18.00
2020-08-11	Buy	Reiterated by	Mizuho	$10.28	$17.00
2020-07-15	Equal Weight	Target Raised by	Morgan Stanley	$12.35	$11.00 → $12.00
2020-07-15	Buy	Reiterated by	HC Wainwright	$12.35
2020-06-29	Buy	Initiated by	Needham & Company LLC	$12.70	$18.00
2020-05-06	Overweight	Target Raised by	JPMorgan Chase & Co.	$11.64	$13.00 → $18.00
2020-05-06	Equal Weight	Target Raised by	Morgan Stanley	$11.64	$9.00 → $11.00
2020-05-06	Positive - Sector Perform	Target Raised by	Royal Bank of Canada	$11.64	$8.00 → $12.00
2020-05-06	Buy	Target Raised by	HC Wainwright	$11.64	$16.00 → $17.00
2020-05-06	Buy	Target Raised by	Mizuho	$11.64	$15.00 → $17.00
2020-05-05	Buy	Target Raised by	Needham & Company LLC	$11.95	$15.00 → $18.00

AKBA Stock Trend

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $2.96 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.

Given the current short-term trend, the stock is expected to fall -26.10% during the next 3 months and, with a 90% probability hold a price between $1.48 and $2.19 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-22	$1.99	$2.46	$2.94
2021-09-23	$1.97	$2.45	$2.92
2021-09-24	$1.95	$2.43	$2.91
2021-09-27	$1.94	$2.41	$2.89
2021-09-28	$1.92	$2.40	$2.87
2021-09-29	$1.90	$2.38	$2.86
2021-09-30	$1.89	$2.36	$2.84
2021-10-01	$1.87	$2.35	$2.82
2021-10-04	$1.85	$2.33	$2.81
2021-10-05	$1.84	$2.31	$2.79
2021-10-06	$1.82	$2.30	$2.78
2021-10-07	$1.80	$2.28	$2.76
2021-10-08	$1.79	$2.26	$2.74
2021-10-11	$1.77	$2.25	$2.73
2021-10-12	$1.75	$2.23	$2.71
2021-10-13	$1.74	$2.21	$2.69
2021-10-14	$1.72	$2.20	$2.68
2021-10-15	$1.70	$2.18	$2.66
2021-10-18	$1.69	$2.16	$2.64
2021-10-19	$1.67	$2.15	$2.63
2021-10-20	$1.65	$2.13	$2.61
2021-10-21	$1.64	$2.11	$2.59
2021-10-22	$1.62	$2.10	$2.58
2021-10-25	$1.60	$2.08	$2.56
2021-10-26	$1.59	$2.07	$2.54
2021-10-27	$1.57	$2.05	$2.53
2021-10-28	$1.55	$2.03	$2.51
2021-10-29	$1.54	$2.02	$2.49
2021-11-01	$1.52	$2.00	$2.48
2021-11-02	$1.50	$1.98	$2.46

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!